| Previous close | 8.51 |
| Open | 8.50 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 30.00 |
| Expiry date | 2026-01-16 |
| Day's range | 8.50 - 8.51 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireBaxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication
DEERFIELD, Ill., May 13, 2024--Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates. Clinolipid is Baxter’s proprietary mixed oil lipid emulsion that is used to provide calories and essential fatty acids in parenteral (intravenous) nutrition (PN) when oral or enteral nutrition is not possible, insuffici
Simply Wall St.Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Baxter International Inc. ( NYSE:BAX ) will pay a dividend of $0.29 on the 1st of July. This means the annual payment...
Simply Wall St.Baxter International First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Baxter International ( NYSE:BAX ) First Quarter 2024 Results Key Financial Results Revenue: US$3.59b (up 2.2% from 1Q...
© 2024 Yahoo. All rights reserved.